Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 6OTHER 3

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 6Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Hypersensitivity 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Malignancies 1

Interventions

Prednisone 103enzalutamide 76Docetaxel 72Abiraterone Acetate 68Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 39apalutamide 29Prednisolone 27bicalutamide 26Zoledronic Acid 24radium Ra 223 dichloride 22pembrolizumab 22darolutamide 22Goserelin 22Triptorelin Pamoate 17cabazitaxel 16Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × ZD4054 × Clear all
NCT00554229 2016-02-08

ENTHUSE M1

AstraZeneca

Phase 3 Completed
896 enrolled 15 charts
Genitourinary

Prostatic Neoplasms

NCT00314782 2013-03-12

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

AstraZeneca

Phase 1 Completed
44 enrolled
Genitourinary

Prostatic Neoplasms

NCT00090363 2013-01-08

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

AstraZeneca

Phase 2 Completed
447 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT00055471 2012-10-31

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

AstraZeneca

Phase 2 Completed
22 enrolled 17 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00617669 2012-09-10

ENTHUSE M1C

AstraZeneca

Phase 3 Completed
1,494 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

NCT00626548 2012-09-03

ENTHUSE M0

AstraZeneca

Phase 3 Terminated
2,577 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡